Abstract
Drug-induced thrombotic microangiopathy due to an immune reaction is idiosyncratic and not dose-dependent. The classic example is quinine-dependent antibodies resulting in thrombotic microangiopathy due to activation of endothelial cells. Eltrombopag is a thrombopoietin-receptor agonist indicated in resistant chronic immune thrombocytopenia (ITP). This is the first report of full-blown biopsy-proven thrombotic microangiopathy with acute kidney injury (AKI) and nephrotic syndrome (NS) in a patient with chronic ITP who was initiated on eltrombopag therapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
